Elicio Therapeutics (NASDAQ: ELTX) recently received a number of ratings updates from brokerages and research firms:
- 6/18/2026 – Elicio Therapeutics is now covered by LADENBURG THALM/SH SH. They set a “buy” rating and a $12.00 price target on the stock.
- 6/16/2026 – Elicio Therapeutics was downgraded by JonesTrading from “buy” to “hold”.
- 6/15/2026 – Elicio Therapeutics had its “buy” rating reaffirmed by Rodman & Renshaw.
- 6/15/2026 – Elicio Therapeutics had its price target raised by HC Wainwright from $17.00 to $23.00. They now have a “buy” rating on the stock.
- 6/10/2026 – Elicio Therapeutics is now covered by B. Riley Financial, Inc.. They set a “buy” rating and a $27.00 price target on the stock.
- 5/28/2026 – Elicio Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $17.00 price target on the stock.
- 5/16/2026 – Elicio Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
- 4/24/2026 – Elicio Therapeutics had its “sell (e+)” rating reaffirmed by Weiss Ratings.
Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.
Featured Stories
- Five stocks we like better than Elicio Therapeutics
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
- How Does D-Wave’s New Simulator Change the Quantum Computing Landscape?
- Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock
Receive News & Ratings for Elicio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elicio Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
